{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-050372","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.353464+00:00","generated_at":"2026-05-25T01:37:40.479730+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Q32 Bio presents positive Phase 2a results for bempikibart in alopecia areata at AAD 2025","bullets":["Bempikibart showed 16% mean SALT reduction at week 24 vs 2% placebo (p=0.045) in severe/very severe AA patients.","Deepening responses observed post-dosing: 28% mean SALT reduction at week 36 in severe subset; two patients maintained response at week 55.","Well-tolerated safety profile: no Grade 3+ related AEs, no related viral infections; PK and target engagement confirmed.","OLE and SIGNAL-AA Part B (36-week dosing) to start 1H'25; Part B topline data expected 1H'26.","All 12 responding patients maintained or improved hair growth post-treatment, median follow-up 41 weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-050372","json":"https://secwatch.observer/filing/0001193125-25-050372.json","markdown":"https://secwatch.observer/filing/0001193125-25-050372.md","text":"https://secwatch.observer/filing/0001193125-25-050372.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525050372/0001193125-25-050372-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312525050372/d931400d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:37:40.479730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}